

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Evans et al. Examiner: Phillip Gambel, Ph.D.  
Serial No: 08/487,283 Group Art Unit: 1642  
Filed: June 7, 1995  
For: C5-Specific Antibodies For The Treatment Of Inflammatory Diseases

Asst. Commissioner for Patents  
Washington, D. C. 20231

**OFFICIAL**

Supplemental Amendment

In the Claims:

10/12/99

PHILLIP GAMBEL

21 29. (New) Hybridoma 5G1.1 having ATCC designation HB-11625.

21 30. (New) An antibody produced by the hybridoma of claim 29.

Remarks

Claims 1-12, 18-23, and 25-28 are currently pending.

New Claims 29 and 30 have been added by this amendment.  
Support can be found at least at page 45, lines 5 through 10.

The Commissioner is hereby authorized to charge any additional fees which may be required for this application, or credit any overpayment to Deposit Account No. 01-0483.

Respectfully submitted,

Dated: October 12, 1999

By:

*Mark Farber*

Mark Farber  
Attorney for Applicant  
Reg. No. 34,159